Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1105-1113

  Kelly, Kaitlyn J ^a   Wong, Joyce ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Hepatic malignancy; Herpes simplex virus; Oncolytic viral therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; G 207; GAMMA GLUTAMYLTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; HF 10; HSV 1716; IRINOTECAN; MONOCLONAL ANTIBODY; NV 1020; ONCOLYTIC HERPES VIRUS; ONCOVEX; OXALIPLATIN; PANITUMUMAB; R 7020; YTTRIUM 90;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; BLOOD CHEMISTRY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; INTERMETHOD COMPARISON; LIVER CANCER; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; MAXIMUM TOLERATED DOSE; MICROWAVE THERAPY; MULTIPLE DRUG DOSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OPTIMAL DRUG DOSE; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION;

ANIMALS; CAPSID PROTEINS; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; HUMANS; LIVER NEOPLASMS; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS;

EID: 48249141383     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1105     Document Type: Review

References (59)

1. American Cancer Society. Cancer facts and figures 2007. Available from: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf [Last accessed 10 March 2009]
2. Fahy BN, Jarnagin WR. Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. Surg Clin North Am 2006;86:1005-22
3. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007;204:753-61
4. White RR, Jarnagin WR. The role of aggressive regional therapy for colorectal liver metastases. Cancer Invest 2007;25:458-63
5. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999;49:231-55
6. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2001;11:2465-72
7. Morris KT. Song TJ, Fong Y. Recent advancements in diagnosis and treatment of metastatic colorectal cancer to the liver. Surg Oncol 2006;15(3):129-34
8. Picardo A, Karpoff HM, Ng B, et al. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 1998;124:57-64
9. Capdevila J, Saura C, Macarulla T, et al. Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007;33(Suppl 2):S24-34
10. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007; 13:3806-15
11. Woo Y, Adusumilli PS, Fong Y. Advances in oncolytic viral therapy. Curr Opin Investig Drugs 2006;7(6):549-59
12. Yoon M, Spear PG. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 2002;76(14):7203-8
13. Yu Z, Adusumilli PS, Eisenberg DP et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 2007; 15(1):103-13
14. Mellerick DM, Fraser NW. Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state. Virology 1987;158(2):265-75
15. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9(12):967-78
16. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996;93(21):11307-12
17. Markert JM, Parker JN, Buchsbaum DJ, et al. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006;13(3):66-71
18. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193(1):12-21
19. Stiles BM, Bhargava A, Adusumilli PS, et al. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003;134(2):357-64
20. Bennett JJ, Delman KA, Burt BM, et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002;9(11):935-45
21. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13(11):1325-34
22. Gutermann A, Mayer E, Von Dehn-Rothfelser K, et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006
23. McAuliffe PF, Jarnagin WR, Johnson P et al. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000;4(6):580-8
24. Song TJ, Eisenberg DP, Adusumilli PS, et al. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg 2006;104:532-42
25. Adusumilli P, Stiles B, Chan M, et al. Imaging and therapy of malignant pleural mesothelioma. J Gene Med 2006;8(5):603-15
26. Stiles B, Adusumilli P, Bhargava A, et al. Minimally-invasive localization of oncolytic herpes simplex viral therapy of micrometastatic pleural cancer. Cancer Gene Ther 2006; 13(1):53-64
27. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001;15(7):1306-8
28. Kelly K, Brader P, Rein A, et al. Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function. FASEB J 2008
29. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al. Real-time intraopefative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. Ann Surg 2006;243(6):824-32
30. Hu JC, Booth MJ, Tripuraneni G, et al. A novel HSV-1 virus, JS1/34.5-/ 47-, purges contaminating breast cancer cells from bone marrow. Clin Cancer Res 2006;12(22):6853-62
31. Watanabe D, Goshima F, Mori I, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF 10. J Dermatol Sci 2008
32. Fu X, Nakamori M, Tao L, Amato R, Zhang X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007;30(6):1561-7
33. Benencia F, Courreges MC, Conejo-Garcia JR, et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005; 16(6):765-78
34. Nawa A, Nozawa N, Goshima F, et al. Oncolytic viral therapy for, human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol Oncol 2003;91(1):81-8.
35. Carrier MA, Adams LC, Mahller YY, Cripe TP. Widespread intratumoral virus distribution with fractionated injection enables local control of Large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 2005;12(4):407-16
36. Parikh NS, Currier MA, Mahller YY, et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005;44(5):469-78
37. Mahller YY, Vaikunth SS, Currier MA, et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 2007;15(2):279-86
38. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988;166(1):41-51
39. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7(10):867-74
40. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7(10):859-66
41. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 fbflowing intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002;96:398-406
42. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357(9255):525-6
43. Kemeny N, Brown K, Covey A, et al. A Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006;17(12):1214-24
44. Hu JC, McNeish I, Shorrock C, et al. A phase I clinical trial with OncoVEXGM-CSF. Proc Am Soc Clin Oncol 2003;22:185
45. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006;13(8):1078-84
46. Nakao A, Takeda. S, Shimoyama S, et al. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets 2007;7(2):169-74
47. Meignier B, Roizman B. Herpes simplex virus vaccines. Antiviral Res 1985;(Suppl 1):259-65
48. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158(3):602-14
49. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed Owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162(2):313-21
50. Berkowitz C, Moyal M, Rosen-Wolff A, et al. Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immanocompetent mice. Arch Virol 1994;134(1-2):73-83
51. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006;208(2):299-318
52. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3(8):745-50
53. Ebright MI, Zager JS, Malhotra S, et al. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg 2002; 124(1):123-9
54. Bharatan NS, Currier MA, Cripe TP. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediat Hematol Oncol 2002;24(6):447-53
55. Delman KA, Zager JS, Bhargava A. et al. Effect of marine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy. Hepatology 2004;39(6):1525-32
56. Mosesson MW, Natale PD, Amrani DL, et al. Comparison of plasmic hydrolysis of normal fibrinogen and fibrinogen Giessen I. Thromb Res 1978;12(4):693-6
57. Carew JF, Kooby DA, Halterman MW, et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001;4(3):250-6
58. Delman KA, ZagerJS, Bennett JJ, et al. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg 2002;236(3):337-42
59. Dambach MJ, Trecki J, Martin N, Markovitz NS. Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther 2006;13(5):891-8